Novartis Posts 12% Rise in First-Half Net Profits

Strategic Insights -

Novartis, Switzerland's biggest drugs company, saw its first-half net profits increase 12% to SFr4.2 billion, driven by higher margins on its core pharmaceuticals business and a surge in net financial income. This suggests that the company is finally distancing itself from local rival Roche, which has traditionally been more highly regarded for its reputation in discovering successful new drugs. Novartis's pharmaceuticals sales are now growing faster than those of Roche, with an 8% increase in local currency terms to SFr8.5 billion in the first six months of 2000, compared to Roche's 2% growth to SFr8.9 billion.

Key Takeaways:

  • Novartis's first-half net profits increased 12% to SFr4.2 billion, with higher margins on its core pharmaceuticals business and a surge in net financial income.
  • The company's pharmaceuticals sales grew 8% in local currency terms to SFr8.5 billion in the first six months of 2000, outpacing Roche's 2% growth to SFr8.9 billion.
  • Novartis's margins on its pharma operations rose from 29.3% to 30.4%, with the company expecting to maintain its improved margins despite significant spending on product launches.
  • The company's pharmaceuticals, generics, and eyecare divisions reported higher profitability, while consumer health was squeezed by spending on product launches and animal health suffered from increased operations.
  • Dan Vasella, Novartis chairman, attributed the group's first-half performance to "prioritised resource allocation to growth drivers and new product introductions."
  • Vasella warned that the third quarter would be "somewhat softer" and full-year sales would show mid-single-digit growth in local currency terms.

Statistics:

  • First-half net profits: SFr4.2 billion (+12% compared to the same period in 1999)
  • Pharmaceuticals sales (local currency terms): SFr8.5 billion (+8% compared to the same period in 1999)
  • Roche's pharmaceutical sales (local currency terms): SFr8.9 billion (+2% compared to the same period in 1999)
  • Margins on pharma operations: 30.4% (+1.1% compared to the same period in 1999)

Sources:

  • "Novartis profits rise 12% in first half" - The Financial Times, July 2000
  • "Novartis sets apart higher operating gains" - Bloomberg News, July 2000